# Fingolimod Reduces T1 Hypointense and Gadolinium Enhancing Lesions in Hispanic MS Patients





Eduardo R. Estades, MD<sup>1,2,</sup> Angel R. Chinea MD.<sup>2</sup>, Kenneth Stein, MD<sup>2,</sup> Yatzka G. Hernández MD.<sup>2</sup>,

Ivonne Vicente, MD.<sup>2</sup>, Christina Rubi<sup>2</sup>

Background

Fingolimod (FG) is a sphingosine-1phosphate (S1P) receptor modulator that is FDA approved for the treatment of Multiple Sclerosis (MS)<sup>1</sup>. MS is frequent in Puerto Rico with an incidence of 5.0/100,000 and affecting individuals in the peak of their life<sup>2</sup>. Following patient's T1 gadolinium (GAD) lesion enhancement and T1 hypo intense lesions or black holes (BH) with MRI imaging have become standard in patient care.

### **Objectives**

To determine if FG can reduce T1 GAD lesions and BH burden in a Hispanic population with MS (Figure 1-4).

### Methods

117 Hispanic patients with MS were recruited from a single MS center all diagnosed by a neurologist. Patient recruitment enrollment was open regardless of age. Patients less than 18 years of age had parental consent. Patients had baseline and follow-up imaging at a designated MRI center using a 1.5 T MRI with MS imaging protocol. Three patients had their baseline and follow up MRIs at another MRI center. These 3 images and reports were submitted to the designated MRI center to reduce inter-radiologist bias. All images were interpreted by one neuroradiologist. The neuroradiologist compared baseline and 1 year-follow up images to determine the absence, presence or development of T1 GAD-(BH) T1 hypointense and enhancing (GAD).






Figure 1. Gender Distribution








Figure 3. Most patients had prior exposure to DMTs at enrollment

Christiana Care Health System, Delaware<sup>1</sup>, San Juan MS Center-Caribbean Center for Clinical Research, Puerto Rico<sup>2</sup> www.caribbeanneurologicalcenter.com; achinea@me.com, eduardo.estades@christianacare.org

## **Results**

94/117 completed the first year. The majority of patients were Relapsing Remitting (Figure 4) and had prior use of disease modifying therapy (Figure 3). Women composed the majority of patient population (81%). More than 50% of the population had less than 5 years with the disease. 1/3 of the population was diagnosed between the ages of 30-45 years old. At baseline, there were 50 patients without BH and 44 patients with BH. At 1 year follow up, 88% (44) BH negative patients did not developed BH and 87% (43) of patients with BH at baseline did not develop new BH. 1 patient with BH at baseline, had resolution of their solitary black hole at 1 year follow up and was deemed transitory BH. At baseline, there were 71 patients without GAD enhancing lesions and 23 patients with GAD enhancing lesions. At 1 year follow up, 96% of GAD negative patients did not have GAD enhancement and 87% of patients GAD enhancing lesions at baseline did not develop GAD enhancing lesions. 10 patients were lost to follow up and 13 patients discontinued the medication. Reasons for patient discontinuation: 4 headaches, 4 generalized malaise, 1 lack of efficacy, 2 cost of medication, 1 developed psychotic symptoms, 1 developed macular edema.

T1 Gadolinium Enhancement Negative Patients at Baseline		T1 Gadolinium Enhancement Positive at Baseline		
GAD negative at baseline	71	GAD positive at baseline	23	
GAD negative at 1 year	68	GAD negative at 1 year	20	
GAD enhacement lesions at 1 year	3	GAD positive at 1 year	3	
% of Patients that remained Gad negative at 1 year	96%	Reduction in GAD enhancement lesions at 1 year	87%	Fi
T1 Black Hole Negative at Baseline		T1 Black Hole Positive at Baseline		СС
T1 BH negative	50	T1 BH Positive at Baseline	44	Pasu
T1 BH positive at 1 year	6	Development of T1 BH at 1 year	0	1.
% of patients that did not develop BH at 1 year	88%	Transitory BH	1	2.
		% of patients with stable T1 BH burden at 1 year	87%	

We can conclude that FG is highly effective in reducing both T1 Gadolinium enhancement lesion and development/progression of T1 hypointense lesions. The data suggests that FG can be considered when treating Hispanic patients with MS. More information is needed to study the long-term efficacy of this medication. This 2year study has finished and is currently being analyzed.

igure 4. Relapsing Remitting was the common frequent subtype at enrollment. Patients did not progress to another ubtype.

73



#### Conclusion

#### **MS SUBTYPE DISTRIBUTION**

Relapsing Remitting

Secondary Progressive

Clinically Isolated Syndrome

Radiologicall y Isolated Syndrome

ID DX28

#### References

Gilenya [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; April 2014.

Chinea AC, Rubi C, Estades E, Rios C, Vicente I, Hernandez Y. Incidence of Multiple Sclerosis in Puerto Rico: A Multicenter Initiative. Poster presented in Ectrims 2015.